today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate the Company’s Cell Pouch auto-transplanted with ...

Aro Biotherapeutics Announces U.S. FDA Clearance of IND Application for ABX1100 for Potential Treatment of Late-Onset Pompe Disease (LOPD) Announcement coincides with WORLDSymposium ...

“FDA clearance of our IND application, combined with the encouraging data from our phase 1 healthy volunteer trial, provide tremendous momentum for the ABX1100 clinical development program ...

“Clearance of the IND application for CNP-103 is a notable moment for COUR, as CNP-103 will be our third proprietary autoimmune disease program developed using our nanoparticle platform for ...

IND, application for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR T product. The Phase 1 RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ...

The company plans to submit an Investigational New Drug Application (IND) for IO112 to the US FDA in 2025 as part of its ongoing commitment to develop innovative cancer treatments. IO112 is ...